In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to EAPC Ivory (& above) Members, Fellows of the ESC and Young combined Members

Risk Or Benefit IN Screening for CArdiovascular Disease (ROBINSCA): the rationale and study design of a population-based randomised-controlled screening trial for cardiovascular disease

Session Poster Session 2

Speaker Carlijn Van der Aalst

Congress : ESC Preventive Cardiology (Formerly EuroPrevent) 2019

  • Topic : preventive cardiology
  • Sub-topic : Secondary Prevention
  • Session type : Poster Session
  • FP Number : P545

Authors : C M Van Der Aalst (Rotterdam,NL), M Vonder (Groningen,NL), J-W Gratama (Apeldoorn,NL), H Adriaansen (Apeldoorn,NL), D Kuijpers (The Hague,NL), S Denissen (Rotterdam,NL), P Van Der Harst (Groningen,NL), RL Braam (Apeldoorn,NL), PRM Van Dijkman (The Hague,NL), M Oudkerk (Groningen,NL), HJ De Koning (Rotterdam,NL)

C M Van Der Aalst1 , M Vonder2 , J-W Gratama3 , H Adriaansen4 , D Kuijpers5 , S Denissen1 , P Van Der Harst6 , RL Braam7 , PRM Van Dijkman8 , M Oudkerk2 , HJ De Koning1 , 1Erasmus Medical Center, Public Health - Rotterdam - Netherlands (The) , 2University Medical Center Groningen, Radiology - Groningen - Netherlands (The) , 3Gelre Hospital of Apeldoorn, Radiology - Apeldoorn - Netherlands (The) , 4Gelre Hospital of Apeldoorn, Clinical Chemistry and Laboratory Medicine - Apeldoorn - Netherlands (The) , 5Bronovo Hospital, radiology - The Hague - Netherlands (The) , 6University Medical Center Groningen, Cardiology - Groningen - Netherlands (The) , 7Gelre Hospital of Apeldoorn, cardiology - Apeldoorn - Netherlands (The) , 8Bronovo Hospital, cardiology - The Hague - Netherlands (The) ,



Coronary Heart Disease (CHD) remains a major cause of morbidity and mortality worldwide. The aim is to describe the rationale, study design, and first results of the Dutch Risk Or Benefit IN Screening for CArdiovascular disease (ROBINSCA) trial, the first population-based randomised-controlled Computed-Tomography screening trial for cardiovascular disease, powered to detect a benefit of 15% reduced CHD-morbidity and mortality.


Addresses of men (aged 45-74 years) and women (aged 55-74 years) were obtained (n=394,058) from the population registry. All received a mailing with an information brochure, a questionnaire and waist measurement tape and an informed consent form. Asymptomatic people with an expected high-risk for developing CHD were randomised (1:1:1) to one of the study arms: intervention arm A (screening by traditional risk factors), intervention arm B (screening by Coronary Artery Calcium scoring only) or the control arm (usual care).


A total of 87,866 (22.3%) people responded to the questionnaire, of which 43,447 (49.4%) were randomised to intervention arm A (n=14,478 (33.3%)), intervention arm B (n=14,450 (33.3%)), or the control arm (n=14,519 (33.4%)). Screening was completed in August 2018. In intervention arm A, 12,184 (84.2%) were screened and in 54.9% risk reducing treatment by the general practitioner was advised. In intervention arm B, 12,950 (89.6%) were screened and only 24% were advised to receive risk reducing treatment.


CHD-related morbidity and mortality will be measured at 5-year of follow-up. Evidence for net-effectiveness of population-based screening for cardiovascular risk in an asymptomatic population will possibly enable large health gains.

Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are